WSC 2023 | ENCHANTED3-MT trial: defining ideal blood pressure post-thrombectomy

While the ENCHANTED2 trial (NCT04140110) established that lowering systolic blood pressure below 120mmHg is detrimental to patients, the ideal blood pressure target after endovascular thrombectomy for acute ischemic stroke remains uncertain. The trial randomized more than 800 patients 1:1 to more-intensive (target SBP ≤120mmHg within 1 hour) or less-intensive (target SBP 140-180mmHg) BP management over 72 hours, finding that more intensive BP lowering was associated with worse functional outcomes and more early neurological deterioration. Lili Song, MD, PhD, The George Institute for Global Health China, Beijing, China, introduces the subsequent ENCHANTED3-MT trial, aimed at defining the optimal blood pressure threshold for optimal patient outcomes. The trial will randomize patients into three groups: minimal, moderate, and intensive blood pressure control treatment, setting the lowest limit at 140mmHg. The ENCHANTED3-MT trial is scheduled to commence in early 2024. This interview took place at the World Stroke Congress (WSC) 2023 in Toronto, Canada.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.